一脈陽光(02522.HK)擬收購高脈健康70.0%股權
格隆匯6月22日丨一脈陽光(02522.HK)發佈公吿，2025年6月22日，公司全資附屬公司江西贛江新區一脈陽光健康管理有限公司(“一脈陽光健康管理”)(作為買方)、廣東高尚健康科技集團有限公司(“賣方I”)、廈門高尚醫學影像診斷中心有限公司(“賣方II”)及合肥高尚醫學影像診斷中心有限公司(“賣方III”)(作為賣方，統稱為“賣方”)與廣州高脈健康科技有限公司(“高脈健康”)訂立股權轉讓協議，據此，一脈陽光健康管理將分別向賣方I、賣方II及賣方III收購高脈健康的30.0%、20.0%及20.0%股權，總代價為人民幣5400萬元。
於本公吿日期，一脈陽光健康管理並無持有高脈健康的任何股權，而高脈健康由賣方I、賣方II及賣方III分別擁有60.0%、20.0%及20.0%股權。收購事項完成後，一脈陽光健康管理將擁有高脈健康70.0%的股權，高脈健康將成為公司的附屬公司，其財務業績將綜合併入集團的財務報表。
高脈健康為一家根據中國法律註冊成立的有限公司，主要從事核醫學影像技術以及運營管理服務業務。作為中國第三方醫學影像服務行業兩家頭部企業，公司與賣方I繼2025年1月簽署全面戰略合作協議後，進一步通過收購事項深化合作實現強強聯合，雙方的合作將進一步發揮各自經驗與優勢，通過創新業務模式、專業的醫療團隊、領先的專科技術，共同探索第三方醫學影像服務行業的重要歷史機遇。
具體而言，(1)通過收購事項，基於賣方I多年以來在核醫學領域積累的項目資源、學科能力和專業經驗，補充和強化本集團在核醫學項目上開發、管理和運營端的能力。雙方共同致力於探索和建立對於在醫院核醫學項目的創新投資、運營和推廣模式；(2)雙方共同推動放射性藥物新藥合成在PET/CT業務推廣中的應用，依託賣方I在放射性藥物研發和生產端的能力優勢，藉助集團在醫學影像產業鏈的深度佈局，進一步推廣放射性藥物新藥在核醫學領域的新技術、新方法和新應用，提升核醫學的精準診斷能力；(3)雙方共同藉助彼此的品牌優勢、專業資源以及行業渠道，共同聯合進行第三方醫學影像中心市場的推廣。雙方共同致力於在包括互聯網醫院影像服務線上開單線下檢查創新模式的打通、醫學影像服務和相關產品能力的海外市場拓展、“一縣一核醫學科”政策下的核醫學區域業務深度開發、創新性醫學影像服務產品推廣、醫學影像數據資產價值發掘和影像診斷AI的探索等戰略方向的深化推進。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
